http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
-
Simulations Plus Outlines Paths to Win at 2023 Investor Day
-
ISoP New Board of Trustees Members Announced
-
Simulations Plus to Host Investor Day on Tuesday, November 14th
-
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
-
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
-
Simulations Plus (SLP) Receives New FDA Grant Award
-
Simulations Plus Receives New FDA Grant Award
-
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
-
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
-
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
-
Simulations Plus Releases ADMET Predictor® 11
-
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
-
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
-
Simulations Plus (SLP) Acquires Immunetrics
-
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
-
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
-
Simulations Plus (SLP) Receives FDA Renewal for DILIsym Software Licenses
-
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
-
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
-
MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science
-
Simulations Plus (SLP) Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
-
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
-
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
-
Simulations Plus to Present at Sidoti March Small-Cap Conference
-
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
-
Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1
-
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
-
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
-
Simulations Plus (SLP) and Global Agrochemicals Leader to Collaborate on Machine Learning Models
-
Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
-
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
-
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
-
Simulations Plus (SLP) Executes $20M Accelerated Share Buyback
-
Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
-
Simulations Plus Reports First Quarter Fiscal 2023 Financial Results
-
Simulations Plus Sets Date for First Quarter Fiscal Year 2023 Earnings Release and Conference Call
-
Simulations Plus (SLP) and the University of Bath Awarded New FDA Grant
-
Simulations Plus and the University of Bath Awarded New FDA Grant
-
Gustavo Mendes Lima Santos Joins the Simulations Plus Regulatory Fellowship Program
-
Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code
-
Simulations Plus (SLP), University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products
-
Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products
-
Simulations Plus Reports Fourth Quarter and Full Fiscal Year 2022 Financial Results
-
Simulations Plus Announces Cash Dividend
-
Simulations Plus Releases GastroPlus® Version 9.8.3
-
Simulations Plus Sets Date for Fourth Quarter and Fiscal Year 2022 Earnings Release and Conference Call
-
Simulations Plus to Present at Sidoti Fall Small Cap Investor Conference
-
Simulations Plus to Present at Baird 2022 Global Healthcare Conference
-
Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease

